Lilly and the AACR Work Together To Recognize Breakthrough Research in the Fight Against Cancer

Los Angeles (ots/PRNewswire) -

- Awards Presented for Substantial Contributions to Cancer
Research

Innovative and collaborative cancer research can be the catalyst
to improving patient outcomes. Celebrating the 100th anniversary of
the American Association for Cancer Research (AACR) at the 2007 AACR
Annual Meeting in Los Angeles, Eli Lilly and Company in partnership
with AACR presented two awards, which acknowledge innovation and the
growing importance of interdisciplinary teams working together to
transform research discoveries into clinical practice.

"Both the Team Science Award and the G.H.A. Clowes Memorial Award
allow us to recognize individuals and teams who are working to bring
meaningful progress to the future of cancer care," said Richard
Gaynor, M.D., vice president, cancer research and global oncology
platform leader at Lilly. "Their work is occurring at hospitals,
research organizations, pharmaceutical and biotechnology companies
and government institutions. The breakthroughs delivered by these
award recipients can form the backbone of the next phase of cancer
treatments. At Lilly, we are collaborating with researchers around
the world to identify the best ways to deliver the right medication
at the right dose and the right time for patients. This gives the
medical community and patients more powerful options in the fight
against cancer."

The first-ever Team Science Award was presented to a collaborative
16-member team from the University of Michigan and Harvard
University-Brigham and Women's Hospital. The two universities worked
together to uncover a breakthrough finding -- a unique change
involved in the pathogenesis of prostate cancers -- which has
profound clinical and biological implications for understanding not
just prostate cancer but possibly other common solid tumors.

Selected from a pool of nearly 30 applicants, the Michigan and
Harvard team was collectively awarded a prize of US$50,000. In
addition to their prize, the institutions will be cited for their
collaboration and contribution to team science.

Also presented was the G.H.A. Clowes Memorial Award recognizing an
individual with outstanding recent accomplishments in basic cancer
research. The award was presented to Michael Kastan, M.D., Ph.D.,
cancer center director at St. Jude Children's Research Hospital in
Memphis, Tennessee, for his leadership in studying cellular responses
to DNA damage. Lilly and the AACR established the award in 1961 to
honor Dr. G.H.A. Clowes, a former research director at Lilly and an
active member of AACR. Dr. Kastan will be awarded US$30,000 and will
deliver a lecture on his research findings during the 2007 AACR
Annual Meeting.

"It is an honor to recognize Dr. Kastan with the Clowes Award and
the collaborative team from the University of Michigan and Harvard
University with the Team Science Award," said Gaynor. "Their work
provides meaningful knowledge of how we may be able to find new and
innovative treatments to combat this deadly disease."

About AACR

The mission of the American Association for Cancer Research is to
prevent and cure cancer. Founded in 1907, AACR is the world's oldest
and largest professional organization dedicated to advancing cancer
research. The membership includes more than 24,000 basic,
translational, and clinical researchers; health care professionals;
and cancer survivors and advocates in the United States and more than
70 other countries. AACR marshals the full spectrum of expertise from
the cancer community to accelerate progress in the prevention,
diagnosis and treatment of cancer through high-quality scientific and
educational programs. It funds innovative, meritorious research
grants. The AACR Annual Meeting attracts more than 17,000
participants who share the latest discoveries and developments in the
field. Special Conferences throughout the year present novel data
across a wide variety of topics in cancer research, treatment, and
patient care. AACR publishes five major peer-reviewed journals:
Cancer Research; Clinical Cancer Research; Molecular Cancer
Therapeutics; Molecular Cancer Research; and Cancer Epidemiology,
Biomarkers & Prevention. Its most recent publication, CR, is a
magazine for cancer survivors, patient advocates, their families,
physicians, and scientists. It provides a forum for sharing
essential, evidence-based information and perspectives on progress in
cancer research, survivorship, and advocacy.

About Lilly Oncology, a Division of Eli Lilly and Company

For more than four decades, Lilly Oncology has been collaborating
with cancer researchers to deliver innovative treatment choices and
valuable programs to patients and their physicians. Inspired by
courageous patients living with cancer, Lilly Oncology is providing
treatments that are considered global standards of care and
developing a broad portfolio of novel targeted therapies to
accelerate the pace and progress of cancer care. To learn more about
Lilly's commitment to cancer, please visit www.LillyOncology.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of first-in-class and best-in-class pharmaceutical
products by applying the latest research from its own worldwide
laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides
answers -- through medicines and information -- for some of the
world's most urgent medical needs.

O-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

Web site: http://www.LillyOncology.com

ots Originaltext: Eli Lilly and Company
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Christine Van Marter of Eli Lilly and Company, +1-317-651-1473, or
cell, +1-317-554-7923, vanmarterch@lilly.com; Photo: NewsCom:
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO, PRN Photo Desk,
photodesk@prnewswire.com